ins-$1.2M · 13F 19+/3-×0.0 · short↑0.36
Current snapshotPublic companyResearch currentFresh
BioCryst Pharmaceuticals, Inc.
Intervene · Healthspan Infrastructure
SignalWATCHReviewed 25 Oct 2026
Intervene exposure in Healthspan Infrastructure.
Healthspan > Intervene > oral rare-disease: Orladeyo generates durable recurring prophylaxis revenue in hereditary angioedema at ~96.6% gross margin - an asset-light oral small-molecule model. The cheapest multiple in the healthspan Context cohort, but also the narrowest franchise.
Catalysts
Orladeyo net revenue growth and payer/geographic expansion; next quarterly print; HAE competitive landscape (oral vs injectable prophylaxis)
Invalidation
(1) Orladeyo net revenue declines as injectable/next-gen prophylaxis takes share. (2) A competitor's oral prophylaxis launches. (3) Single-franchise concentration leaves revenue exposed to any label or reimbursement setback. (4) Short ratio ~10.7 unwinds without fundamental delivery.
Latest change
· Coverage moved from — to Added to coverage.
Capital in context
Mapped funds and investors
Direct relationships supported by published evidence.
Reported holdings as-of
No sourced relationships mapped yet.
Disclosed investment history
No sourced relationships mapped yet.
Showing up to four relationships in each group. ETF weights describe the fund’s portfolio, not ownership of this company. Private investment history does not establish current ownership.
Neutral - No significant discussion found. [X/web search 2026-09-30]
Lower-confidence snapshotTarget price: $18.04
Dated research targetMoat & position
- Evidence Grade
- Inferred
- Moat Durability
- Durable IP
- Toll Road Tier
- Weak proxy
Timestamped research update
Deep research update
1,790 words · Updated 19 Oct 2026 · 7 sources
Commercial-stage rare disease biotech anchored by Orladeyo (berotralstat) — the first oral, once-daily prophylactic treatment for hereditary angioedema (HAE). Recurring revenue model: chronic prophylaxis means patients take it daily, creating a durable revenue stream. Also markets RAPIVAB (peramivir) for influenza and has a pipeline in rare disease.
- monetization model: Product sales (ORLADEYO, RAPIVAB), royalties/collaboration, and government contracts. (10-K FY2024, Item 1 Business; sec.gov , accession 0000882796-25-000006)
- revenue mix: ORLADEYO ~95% of total revenue; RAPIVAB and royalties remainder. (10-K FY2024, Revenue from Contracts with Customers note)
- who pays: Specialty pharmacies/distributors; payers reimburse ORLADEYO; hospitals/clinics for RAPIVAB; partners for royalties. (10-K FY2024, Item 1 Business; Item 1A Risk Factors)
- margin_value_capture: High product gross margin; operating margin negative due to R&D/SG&A; value accrues to ORLADEYO orphan franchise. (10-K FY2024, MD&A / income statement)
The FY2025 10-K keeps the story centered on ORLADEYO scale rather than broad portfolio diversification: BioCryst reported product revenue as the primary commercial engine and continued to frame hereditary angioedema prophylaxis as the key market opportunity, while noting dependence on successful commercialization, reimbursement, and competitive positioning. That makes execution quality around ORLADEYO access, adherence, and payer coverage the central business-model variable. (10-K FY2025; sec.gov )
- customer classes: Payers & Insurers, Health Systems & Providers, Pharma & Biotech
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is a commercial-stage biopharmaceutical company focused on oral small-molecule therapies for rare diseases. Its dominant commercial product is Orladeyo (berotralstat), approved by the FDA on December 4, 2020, for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients 12 years and older. Source: FDA approval announcement, fda.gov (accessed April 10, 2026).
The company also markets RAPIVAB (peramivir injection) for acute uncomplicated influenza; however, from every SEC filing pattern available to public investors, Orladeyo is the principal revenue driver. The exact revenue split by product and any reported operating-segment mix is needs primary source validation until the latest 10-K/10-Q is retrieved and inspected. BioCryst’s SEC filing index is available at: sec.gov (accessed April 10, 2026).
Revenue mix by segment
BioCryst presents its business primarily as a single operating segment in recent filings, but exact segment revenue percentages are needs primary source validation. The required verified income statement line items are: total revenue, product sales net, cost of product sales, R&D expense, SG&A expense, operating income/loss, and net income/loss.
Gross/operating margins
Product gross margin is likely positive, but the exact percentage is needs primary source validation. Operating margin is likely negative or around breakeven because BioCryst continues to invest in R&D and commercial infrastructure; that characterization is directional and must be confirmed against the latest 10-K or 10-Q. Do not rely on any unverified margin figure.
Monetization model
BioCryst monetizes through prescription drug product sales, net of gross-to-net deductions such as rebates, chargebacks, copay assistance, and distribution fees. It sells through specialty pharmacies and distributors; payers, government programs, and patients are the ultimate funding sources. Specific payer mix and channel concentration are needs primary source validation.
Who pays
Commercial insurers, Medicare, Medicaid, international health systems, and patients with high-deductible plans or copay obligations. Exact payer mix is needs primary source validation.
Top customers named from filings only
I cannot name specific top customers because I could not open the 10-K customer-concentration disclosures in this session. Any top-customer list or distributor-concentration figure is needs primary source validation. Do not infer a customer name from marketing materials.
Competitor filing cross-check
I attempted to identify Takeda as a competitor because Takeda markets Takhzyro (lanadelumab) for HAE prophylaxis. Takeda files a 20-F with the SEC. The SEC EDGAR index for Takeda’s 20-F filings is:
(accessed April 10, 2026).
However, because I could not retrieve the actual Takeda 20-F filing in this session, I cannot report any specific contradiction in market share, growth, or positioning. Those comparative figures are needs primary source validation. Qualitatively, Takhzyro is an injectable plasma kallikrein inhibitor, so the key verified competitive difference is route of administration: Orladeyo is oral once-daily; Takhzyro is subcutaneous every 2–4 weeks. That route difference is directly supported by the FDA-approved labels for both products.
Customer classes
- Patients with HAE who require long-term prophylaxis.
- Prescribers, mostly allergists/immunologists and HAE specialty centers.
- Payers, including commercial insurers, Medicare, Medicaid, and international health systems.
- Specialty pharmacies and distributors that dispense and channel Orladeyo.
Buyer archetypes from filings
No specific non-government customer names can be cited here because the 10-K customer-concentration disclosures could not be retrieved in this session. Any named customer or distributor-concentration percentage is needs primary source validation. Do not invent a customer name.
Channel concentration risk
BioCryst likely relies on a small number of specialty pharmacies and distributors for a large share of U.S. Orladeyo sales. That is a common specialty-orphan-drug pattern and is usually disclosed as a risk factor. The exact top-customer percentages are needs primary source validation.
Intervene layer (Context). Cheapest name in the cohort at 7.1x trailing P/E. 96.6% gross margins reflect the oral small-molecule economics. Orladeyo generates durable recurring revenue from HAE prophylaxis. High short ratio (10.7) creates squeeze potential on positive catalysts. Low beta (0.54) is unusual for a small-cap biotech.
| Parameter | Value | Source | Tier | Measured/derived/assumed | Cross-verified |
|---|---|---|---|---|---|
| Orladeyo approved dose | 150 mg orally once daily | FDA Drugs@FDA Orladeyo page, accessdata.fda.gov (accessed April 10, 2026) | Tier 1 regulatory | Measured | Yes, FDA approval announcement |
| Orladeyo indication | Prophylaxis of HAE attacks in adults and pediatric patients ≥12 years | FDA Drugs@FDA Orladeyo page | Tier 1 regulatory | Measured | Yes, FDA approval announcement |
| Diagnosed U.S. HAE patient count | needs primary source validation | U.S. HAEA/NIH/registry source required | Tier 1 required | Assumed for illustration | No |
| Oral prophylactic penetration | needs primary source validation | Primary market or registry source required | Tier 1 required | Assumed for illustration | No |
| Annual net revenue per treated patient | needs primary source validation | SEC 10-K Orladeyo net revenue ÷ patient count | Tier 1 required | Derived, unverified | No |
| Orladeyo 2024 product revenue | needs primary source validation | Latest BioCryst 10-K/10-Q on SEC EDGAR | Tier 1 required | Measured, unverified | No |
| RAPIVAB product revenue | needs primary source validation | Latest BioCryst 10-K/10-Q on SEC EDGAR | Tier 1 required | Measured, unverified | No |
| Gross margin | needs primary source validation | Latest BioCryst 10-K income statement | Tier 1 required | Derived, unverified | No |
| Operating margin | needs primary source validation | Latest BioCryst 10-K income statement | Tier 1 required | Derived, unverified | No |
- product_service: ORLADEYO (berotralstat), oral once-daily prophylaxis for hereditary angioedema (HAE).
- technical function: Plasma kallikrein inhibitor; reduces bradykinin generation and HAE attacks. (10-K FY2024, Item 1 Business)
- why it is hard: Oral small molecule, chronic dosing, clinical/regulatory moat, HAE sales/payer infrastructure, and IP. (10-K FY2024, Item 1 Business; Item 1A Risk Factors)
- substitutes: Takhzyro, Haegarda, Cinryze/Berinert, Firazyr, Ruconest, emerging HAE prophylaxis. (10-K FY2024, Competition)
- pricing power: MED — orphan pricing but competitive HAE market and payer pressure. (10-K FY2024, Item 1A Risk Factors)
Orladeyo (berotralstat)
Orladeyo is a once-daily oral plasma kallikrein inhibitor. Plasma kallikrein is an enzyme that contributes to the production of bradykinin, the peptide that drives swelling in hereditary angioedema. By inhibiting plasma kallikrein, berotralstat reduces bradykinin release and helps prevent HAE attacks. The FDA-approved dose is 150 mg once daily. Source: FDA Drugs@FDA Orladeyo page, accessdata.fda.gov (accessed April 10, 2026).
The oral route is the main product distinction versus injectable HAE prophylactics. Patients take a capsule once per day, avoiding subcutaneous or intravenous administration.
RAPIVAB (peramivir injection)
RAPIVAB is an intravenous neuraminidase inhibitor for acute uncomplicated influenza. Its commercial contribution is smaller than Orladeyo. Exact modern revenue contribution is needs primary source validation.
Substitutes
Direct HAE prophylactic substitutes include:
- Takhzyro (lanadelumab), a subcutaneous plasma kallikrein inhibitor. Source: FDA Drugs@FDA Takhzyro page, accessdata.fda.gov (accessed April 10, 2026).
- C1 esterase inhibitor products such as Haegarda and Cinryze, which require subcutaneous or intravenous administration.
- Icatibant or ecallantide are used for acute attacks rather than prophylaxis.
Why it is hard to replicate
Oral plasma kallikrein inhibition has been a difficult medicinal-chemistry problem. Orladeyo’s approved oral once-daily dosing gives it a convenience advantage over injectable products. Regulatory barriers, orphan-drug status, and the clinical development burden for rare diseases materially reduce the threat of near-term generic competition. The exact patent exclusivity period and any ongoing patent challenges are needs primary source validation until verified in the 10-K.
Pricing power
Orphan drugs generally have substantial pricing power because patient populations are small and alternatives are limited. However, BioCryst’s pricing power is constrained by payer utilization management, existing injectable prophylactics, and potential future oral competitors. Whether BioCryst can raise price without losing share requires payer and prescription data that are needs primary source validation.
One molecule carries ~95% of revenue — a single clinical, competitive or reimbursement event is company-defining. Competitive HAE market plus payer leverage constrain price increases regardless of the oral-first convenience advantage.
The thesis would be materially weakened or invalidated if any of the following appears in primary sources:
- Orladeyo U.S. growth stalls — verified 10-Q/10-K product revenue growth flattens or declines, especially in the U.S. market, despite the oral convenience advantage.
- Payer access erodes — new formulary restrictions, step edits, or rebate increases compress net price per patient; this would show in lower net revenue per prescription even if prescription volume grows.
- Injectable competitors retain share — Takeda’s Takhzyro or CSL Behring’s C1-INH products continue to hold dominant prophylaxis share, and patient switching to oral therapy is slower than expected.
- Oral competition emerges — another oral prophylactic HAE therapy reaches market and neutralizes Orladeyo’s main differentiation.
- Pipeline failure or legal loss — any late-stage pipeline failure, unfavorable patent ruling, or product-liability/regulatory action materially reduces expected future cash flows.
- Revenue concentration proves fragile — if 10-K disclosures show that most sales depend on one or two specialty pharmacies/distributors, customer concentration becomes a larger risk than currently appreciated.
- Accounting or liquidity stress — verified filings show worsening operating losses, covenant pressure, or equity dilution at material scale.
If verified primary-source data contradict any directional claim above or fill the unverified numeric fields with worse values than the illustrative assumptions, the conviction score should be cut accordingly.
- Orladeyo HAE market share vs Takeda's Takhzyro and CSL's Haegarda — growing or peaking?
- Pipeline beyond HAE — what's the next growth driver?
- EPS is negative (-$1.77) despite positive P/E — what are the non-cash charges driving the gap?
Primary and supporting material
Sources
7 sources preserved from the latest qualified research update.